In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business News, In Brief

Executive Summary

Updates on Sandoz' enoxaparin, J&J's Hep C business, Abbott and Watson.

You may also be interested in...



Sandoz GMP Warning Letter: Is The Problem Documentation, Or Leadership?

Upper management at Novartis and Sandoz are responsible for repeated cGMP violations at three Sandoz plants, FDA suggests. The agency’s warning letter, aimed at three sites in North Amercia, includes what may become new biolerplate instructions on drug shortages.

Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset

The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.

Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months

Analysts see break-up as an effort to unlock value for proprietary pharmaceuticals unit, where expectations of slowing Humira sales may have left the company undervalued.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel